In the United States, the Food and Drug Administration (FDA) approved Merck's new medication, Lipfendra, on Thursday, July 16, 2026. This approval is significant as it marks the first noninjectable treatment that targets the liver protein PCSK9, which plays a crucial role in cholesterol management. The drug is intended for patients whose cholesterol levels remain high despite the use of statins, the standard treatment for reducing heart attack risk. Statins work by inhibiting the liver's production of cholesterol, but many patients still struggle to achieve optimal LDL cholesterol levels. The approval was based on two clinical studies involving high-risk patients who were already on standard treatments, including statins. In the first study, which included 3,000 participants, those taking Lipfendra experienced a reduction in LDL cholesterol levels by more than 55% after six months. The second study showed an average reduction of 59% in LDL cholesterol compared to a placebo group. These results indicate that Lipfendra can provide significant benefits for patients who have not achieved their cholesterol goals with statins alone. Despite the promising results, there are some important considerations for patients. The pill must be taken on an empty stomach to ensure its effectiveness. Additionally, while the side effects reported, such as dizziness and diarrhea, were similar between those taking Lipfendra and those on a placebo, patients should be aware of these potential issues. The FDA's review of Lipfendra was expedited under a program designed for promising medications that serve the public interest, highlighting the urgency of addressing high cholesterol and its associated health risks. Heart disease remains the leading cause of death in the United States, with high LDL cholesterol being a major risk factor for heart attacks and strokes. Medical guidelines recommend maintaining an LDL level of at least 70 for individuals with high cholesterol or heart disease, and even lower for those at very high risk. The introduction of Lipfendra could provide a new option for patients struggling to manage their cholesterol levels effectively, potentially improving health outcomes and reducing the risk of cardiovascular events.